X

Trial Profile

Efficacy and safety of everolimus in de novo heart transplant recipients.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Feb 2015

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Ciclosporin; Mycophenolate mofetil
Indications Heart transplant rejection; Renal transplant rejection
Focus Adverse reactions; Therapeutic Use
Sponsors Novartis Pharmaceuticals

Most Recent Events

15 Jul 2009 Primary endpoint 'Creatinine clearance' has not been met; results published in 'Transplantation'.
03 Jun 2009 Results were reported at the American Transplant Congress -- 9th Joint Congress of the American Society of Transplant Surgeons (ASTS) and the American Society of Transplantation (AST).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com